New drug cocktail aims to wipe out breast cancer before surgery
NCT ID NCT07245797
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether adding the drug inavolisib to a standard pre-surgery regimen (pertuzumab, trastuzumab, and nab-paclitaxel) can improve outcomes for people with a specific genetic mutation (PIK3CA) in HER2-positive early breast cancer. About 164 participants will receive either the combo with or without inavolisib before surgery. The main goal is to see if the cancer disappears completely by the time of surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
inavolisib plus pertuzumab and trastuzumab (subcutaneous) and nab-paclitaxel
What this could lead to
If successful, this could point toward a more effective pre-surgery treatment for a specific type of breast cancer, potentially increasing the chance of no cancer remaining at surgery.
What could go wrong
This is a small, early-phase (phase 2) trial, so results may not confirm benefit. Adding inavolisib may also increase side effects without improving outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.